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 CLINICAL PRESENTATION
In September 2012, in Cape Verde, a nephrotic 
syndrome was diagnosed in a 16-year-old boy. Empiric 
treatment was started with prednisolone 1mg/kg 
without achievement of remission. 
In October 2013, the patient was brought to Por-
tugal for treatment. On admission at our department 
the patient presented normal renal function and a 
nephrotic syndrome with oedema, 16 g per day of 
proteinuria, hypoalbuminaemia (1.8 g/dl) and hyper-
cholesterolaemia (290 mg/dl). Serum C3 and C4 were 
normal, ANA and anti-DNA antibodies were negative. 
The presence of hepatitis B, hepatitis C and HIV were 
excluded.
A kidney biopsy was done.
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 HISTOLOGY
In Fig. 1 we can observe a global and homogeneous 
thickening of the capillary walls of the glomerulus. No 
other changes are present. The tubule-interstitial area 
and the medium size artery are normal. This figure is 
representative of the entire biopsy fragment.
Figure 2 shows spike formation along the glomeru-
lar basal membrane (GBM). Figure 3 displays granular 
deposition of IgG globally along the GBM. In Fig. 4 
subclasses of IgG (IgG1, IgG2, IgG3 and IgG4) were 
evaluated and only IgG4 is present along the GBM 
with the same pattern as IgG.
The presence of phospholipase A2 antigen was 
assessed by immunohistochemistry in formaldehyde 
fixed paraffin embedded kidney tissue (clone CL 0474). 
Figure 5-A (deceased-donor kidney) shows the normal 
presence of phospholipase A2 antigen in podocytes. 
In Fig. 5-B (our patient), the GBM shows brown, granu-
lar, deposits. These granules correspond to abnormal 
phospholipase A2 antigen and have the same pattern 
(co-localization) as the IgG and IgG4 deposits.
 Anatomo-clinical diagnosis
Circulating anti-phospholipase A2 antibodies were 
found before any other immunossupression therapy 
was done. The combination of the clinical presenta-
tion, kidney histology and circulating anti- phospho-
lipase A2 antibodies allows the diagnosis of idiopathic 
membranous glomerulopathy.
 TREATMENT AND EVOLUTION
Table 1 displays the treatment done over time and 
the evolution of proteinuria and circulating anti-
phospholipase A2 antibodies.
Figure 3
IgG, immunofluorescence, x 400.
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Figure 4
A – IgG3, immunofluorescence, x 400. B – IgG4, immunofluorescence, x 400.
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CSA – cyclosporine; CYC – cyclophosphamide.
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 DISCUSSION
The thickening of the glomerular basement mem-
brane (GBM) with spike formation by light microscopy 
(Figs. 1 and 2), with fine granular deposits of IgG and 
complement C3 (Fig. 3) by immunofluorescence 
allows the diagnosis of membranous glomerulopathy 
(MG).
The electron microscopy, not done in this case 
and not essential for the diagnosis, is characterized 
by the presence of sub-epithelial electron-dense 
deposits. This histopathological pattern does not 
refer to a unique disease entity: 80% of cases without 
any identified aetiology are referred to as idiopathic; 
the remaining 20% occurring in patients with an 
identified associated clinical condition are classified 
as secondary1.
Over the last 10 years, substantial advances have 
been made in the understanding of the molecular 
pathogenic mechanism of idiopathic MG (iMG). Cir-
culating autoantibodies to phospholipase A2 recep-
tors (anti-PLA2R) were detected in about 70% of 
patients with iMG2. Circulating autoantibodies against 
thrombospondin type-1 domain-containing 7A (THS-
D7A) were detected in 5–10% of the iMG anti-PLA2R 
negative patients3. PLA2R and THSD7A were detected 
in podocytes of normal human glomeruli, and both 
antigens are co-localized with IgG4 deposits on the 
outer aspect of the glomerular basement membrane 
(sub-epithelial) .
 Serological diagnosis
Phospholipase A2 receptor (PLA2R) discovery was 
very quickly translated into clinical practice. Simple 
serologic assays, such as the indirect immuno-
ﬂuorescence test and ELISA, provide speciﬁc, sensi-
tive, and quantitative measurements of circulating 
anti-PLA2R antibodies. Anti-PLA2R antibodies are 
detected in the serum of patients with MG, but not 
in the serum of patients with other nephropathies, 
with autoimmune diseases, or of healthy individuals, 
being highly specific for MG4. 
In a prospective study5, we found that detection 
of anti-PLA2 antibodies had a sensitivity of 57.6% (CI 
39.2-74.5) and a specificity of 100% (CI 47.8-100) [AUC 
0.788; p < 0.0001] for the diagnosis of iMG in a sample 
of patients who had distinct disease stages (active or 
in remission). Hu et al., in a recent meta-analysis6, 
estimated that serum anti-PLA2R level sensitivity and 
speciﬁcity for the diagnosis of iMG in the active stage 
of the disease were 74.0 and 95.0 %, respectively.
A number of recent studies4 showed that circulat-
ing levels of antiPLA2R antibodies were good prog-
nostic biomarkers and enabled precise monitoring 
of the response to immunosuppressive treatment 
(Table I).
 Diagnosis based on kidney tissue 
The PLA2R is weakly expressed in podocytes under 
normal conditions (Fig. 5A) but it is not accessible to 
T cells. Detection of PLA2R antigen in kidney tissue 
(Fig. 5-B) is also an important clue to the diagnosis 
of iMG, and PLA2R is often associated with predomi-
nant or exclusive IgG4 deposits (Fig. 4)7. 
However, presence of PLA2R antigen is commonly 
seen in MG secondary to sarcoidosis or hepatitis B 
infection, and the presence of PLA2R antigen can be 
detected in the absence of circulating anti-PLA2R 
antibodies8. Conversely, in some patients, circulating 
anti-PLA2R antibodies are not associated with PLA2R 
antigen7.
These results led to the recommendation for using 
a combined serological (antibody) and biopsy speci-
men (antigen) analysis in all patients with MG8. 
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